Bicillin L-A Shortage in Australia Worsens: Supply Delayed Until 2027

Pharmacist discussing the Bicillin L-A medicine shortage with a patient at a rural Australian pharmacy, with an empty shelf and supply shortage notice

MEDISEARCHER NEWS

Australia · Medicine shortages · 7 November 2026

In brief

  • Australia’s Therapeutic Goods Administration (TGA) has warned that an expected November shipment of Bicillin L-A 1.2 million-unit injections is unlikely to arrive.
  • The shortage of the 1.2 million-unit prefilled syringe is expected to continue until 31 March 2027.
  • The 600,000-unit Bicillin L-A prefilled syringe remains unavailable, with an expected return-to-supply date of 30 November 2027.
  • The TGA is advising healthcare professionals to consider reserving remaining Australian-registered Bicillin L-A stock for children.
  • Overseas-registered benzathine benzylpenicillin products from Portugal, Spain and the UK have been approved to support supply and are subsidised through the Pharmaceutical Benefits Scheme (PBS), although the UK product is currently unavailable.
  • Patients should speak to their treating healthcare professional about appropriate alternatives rather than interrupting treatment.

Australia’s shortage of Bicillin L-A, an injectable antibiotic used to treat and prevent serious bacterial infections, has worsened after an expected November shipment was delayed.

In an update published on 6 November 2026, the Therapeutic Goods Administration (TGA) confirmed that Pfizer Australia’s anticipated supply of Bicillin L-A 1.2 million-unit injections is unlikely to become available as planned.

The regulator now lists the 1.2 million-unit prefilled syringe as being in shortage until 31 March 2027, while the lower-strength 600,000-unit presentation remains unavailable until 30 November 2027.

The situation is particularly important for people who depend on regular benzathine benzylpenicillin injections to prevent recurrent rheumatic fever and complications such as rheumatic heart disease.

However, the shortage does not mean that all forms of benzathine benzylpenicillin are unavailable in Australia. The TGA has authorised several overseas-registered alternatives, with Pharmaceutical Benefits Scheme (PBS) subsidies supporting patient access.

What has changed in the Bicillin L-A shortage?

The latest development is the expected failure of a November resupply shipment.

Pfizer Australia had been expected to provide additional Bicillin L-A 1.2 million-unit stock during November 2026.

The TGA now says that shipment is unlikely to be available, leaving healthcare services reliant on remaining Australian-registered stock and approved overseas alternatives.

According to the regulator, the current expected supply dates are:

Bicillin L-A presentation Current supply situation Expected return-to-supply date
1,200,000 units / 2.3 mL prefilled syringe Unavailable through normal supply; some existing stock may remain at healthcare services 31 March 2027
600,000 units / 1.17 mL prefilled syringe Unavailable 30 November 2027

These are expected supply dates, not guaranteed delivery dates. The TGA warns that they may change as the manufacturer and regulator continue monitoring availability.

Both presentations are manufactured or supplied in Australia by Pfizer Australia.

What is Bicillin L-A used for?

Bicillin L-A contains benzathine benzylpenicillin, a long-acting injectable form of penicillin.

It is used in the treatment of certain bacterial infections and in the prevention of serious complications associated with those infections.

Important uses include:

  • Rheumatic fever prevention: regular injections may be used to prevent recurrent episodes of acute rheumatic fever.
  • Rheumatic heart disease: ongoing antibiotic prophylaxis can help reduce the risk of further heart damage associated with recurrent rheumatic fever.
  • Syphilis: benzathine benzylpenicillin is an important treatment for certain stages and circumstances of syphilis infection.
  • Group A streptococcal infections: the medicine may be used for specified infections involving the throat or skin.

The TGA also identifies its role in preventing conditions such as congenital syphilis and acute post-streptococcal glomerulonephritis.

Because some patients receive repeated injections over extended periods, an interruption in supply can create more than a temporary inconvenience.

For people receiving secondary prophylaxis against rheumatic fever, maintaining an appropriate treatment schedule is especially important.

Why is the shortage particularly important for children and remote communities?

The TGA has highlighted the importance of benzathine benzylpenicillin for rural and remote healthcare, including its critical role in healthcare for Aboriginal and Torres Strait Islander peoples.

Acute rheumatic fever and rheumatic heart disease remain significant health concerns in some Australian communities, particularly where access to specialist services and consistent healthcare delivery can be challenging.

For patients who require regular antibiotic injections, missed or delayed treatment can increase the risk of recurrent infection-related complications.

The regulator is therefore advising healthcare professionals to consider reserving any remaining Australian-registered Bicillin L-A prefilled syringes for paediatric patients, where clinically appropriate.

This is a supply-prioritisation recommendation, not a statement that adults should go untreated.

Healthcare professionals are being encouraged to use approved overseas-registered alternatives for other patients when suitable.

Which alternatives to Bicillin L-A are available in Australia?

The TGA has approved three overseas-registered benzathine benzylpenicillin products under Section 19A of the Therapeutic Goods Act 1989.

Section 19A allows certain medicines that are registered overseas but not ordinarily registered in Australia to be supplied in specific circumstances, including medicine shortages.

The alternatives listed by the TGA are:

Alternative product Country of registration Supply information
Lentocilin S 1200
Benzathine benzylpenicillin 1,200,000 IU / 4 mL
Portugal Approved for supply; availability should be confirmed with Neon Healthcare
Benzetacil
Benzathine benzylpenicillin 1,200,000 IU
Spain Approved for supply; availability should be confirmed with Phero Pharma
Benzylpenicillin benzathine
1.2 million IU powder for injection, Brancaster Pharma
United Kingdom Approved under Section 19A but currently unavailable

All three products are listed by the TGA as subsidised through the Pharmaceutical Benefits Scheme (PBS).

However, regulatory approval and PBS subsidy do not guarantee that a particular product is currently in stock.

The TGA specifically states that the UK-registered Brancaster Pharma product is currently unavailable, while availability of the other overseas products may vary.

Patients should ask their treating healthcare professional or pharmacy about suitable options and current supply.

Are the imported Bicillin alternatives covered by the PBS?

Yes. The TGA confirms that all three overseas-registered alternatives approved under Section 19A are subsidised through Australia’s Pharmaceutical Benefits Scheme.

This is important because imported medicines can sometimes create additional access or affordability problems during a shortage.

PBS subsidy helps support continued access to the approved alternatives, subject to the applicable prescribing and dispensing arrangements.

However, patients should not assume that every alternative will be immediately available at their usual pharmacy or healthcare service.

Healthcare providers may need to arrange supply through the relevant approval holder.

The TGA identifies the following contacts for healthcare services seeking product availability or ordering information:

  • Lentocilin S 1200: Neon Healthcare — (02) 7255 8455.
  • Benzetacil: Phero Pharma — (02) 9420 9199.
  • Brancaster Pharma product: Pro Pharmaceuticals Group — 1300 077 674. The TGA currently lists this product as unavailable.

Patients should normally discuss supply arrangements with their doctor, pharmacist or healthcare service rather than attempting to source injectable antibiotics independently.

Are the imported alternatives identical to Bicillin L-A?

No. They contain the same type of antibiotic but are not identical presentations.

Australian-registered Bicillin L-A is supplied as a prefilled syringe.

The overseas-registered products are supplied as powders or powder-and-solvent preparations that require reconstitution before administration.

This means healthcare professionals must follow the specific preparation and administration instructions for the product being used.

The TGA has reported difficulties with administering some overseas-registered benzathine benzylpenicillin products and has published additional guidance on appropriate needle sizes.

For example, the regulator lists different recommended needle gauges for Lentocilin S 1200, Benzetacil and the Brancaster Pharma product.

These differences matter because benzathine benzylpenicillin is administered as an intramuscular injection and improper preparation or administration can create avoidable risks.

Patients should not attempt to prepare or inject these alternatives themselves unless they are receiving care under an appropriate clinical arrangement with specific professional instruction.

Important allergy warnings for Bicillin L-A alternatives

The TGA has issued specific allergy advice concerning the imported products.

According to the regulator, Bicillin L-A and the currently approved overseas-registered alternatives contain lecithin of unspecified origin or soy lecithin.

The TGA states that these products are not suitable for patients with allergies to soy or peanuts.

There is also an additional warning for Lentocilin S 1200.

The Portuguese product is packaged with an amber ampoule of diluent containing lidocaine hydrochloride.

That diluent is not suitable for patients with an allergy to lidocaine.

Patients should tell their healthcare professional about relevant allergies before receiving any replacement product.

A clinician must determine whether a particular formulation and its accompanying diluent are appropriate for the individual patient.

What should patients do if they cannot get Bicillin L-A?

The TGA advises patients and carers who cannot access Bicillin L-A to consult their treating healthcare professional.

Depending on the reason for treatment, a clinician may recommend a different brand of benzathine benzylpenicillin or another appropriate antibiotic.

Patients can take several practical steps:

  • Contact the treating clinic early. If you receive regular injections, ask about supply before the next scheduled appointment.
  • Do not independently delay or stop treatment. Missed doses may carry different risks depending on whether the medicine is being used for syphilis, rheumatic fever prevention or another indication.
  • Ask about Section 19A alternatives. Your clinician or pharmacist can assess whether an overseas-registered product is appropriate.
  • Discuss allergies and formulation differences. Imported alternatives may contain excipients or diluents that affect suitability.
  • Confirm supply arrangements. A product being PBS-subsidised does not necessarily mean it is immediately available at every pharmacy.
  • Seek advice if an injection has already been missed. The appropriate response depends on the clinical indication and treatment schedule.

Patients should not attempt to substitute another antibiotic or change the dose or timing without professional advice.

What is the TGA advising healthcare professionals?

The TGA is asking healthcare professionals to manage remaining supply carefully and use the approved alternatives where clinically appropriate.

Its recommendations include:

  • considering reservation of remaining Australian-registered Bicillin L-A stock for paediatric patients;
  • using suitable overseas-registered products for other patients;
  • prescribing or supplying quantities aligned with immediate clinical need rather than automatically dispensing large packs;
  • checking product-specific preparation, reconstitution and administration instructions;
  • reviewing relevant allergy information before administration; and
  • avoiding unnecessary stockpiling.

The regulator notes that Bicillin L-A prefilled syringes are supplied in packs of ten and suggests considering quantities such as one or two dosage units when appropriate to the indication.

This approach is intended to support more equitable distribution of limited supplies while the shortage continues.

Why does Australia need to import antibiotics from Europe?

The Bicillin L-A shortage illustrates how medicine-supply problems can require international coordination even when a treatment is well established.

When an Australian-registered medicine becomes unavailable, the TGA can approve suitable overseas-registered products under Section 19A to help maintain patient access.

In this case, the regulator has authorised products registered in Portugal, Spain and the United Kingdom.

These alternatives can provide a temporary supply pathway, but they also introduce practical differences involving packaging, preparation, administration and availability.

The situation demonstrates why cross-border medicine access is not simply a matter of importing an identical box from another country.

Regulators and healthcare professionals must account for product specifications, patient safety, supply arrangements and reimbursement.

When will Bicillin L-A be back in stock in Australia?

As of the TGA’s 6 November 2026 update, the expected return-to-supply dates are:

  • 31 March 2027 for Bicillin L-A 1.2 million-unit prefilled syringes.
  • 30 November 2027 for Bicillin L-A 600,000-unit prefilled syringes.

These dates are estimates and may change.

The TGA says it will continue working with Pfizer Australia and monitoring the supply situation.

Patients and healthcare professionals can check the regulator’s medicine shortages database for updated availability information.

Frequently asked questions

Is Bicillin L-A unavailable in Australia?

Both Australian-registered Bicillin L-A prefilled syringe presentations are currently listed as unavailable through normal supply. Some remaining stock may still be held by healthcare services, and overseas-registered alternatives have been approved to support access.

When will Bicillin L-A 1.2 million units return?

The TGA currently lists 31 March 2027 as the expected return-to-supply date. An additional shipment expected in November 2026 is now unlikely to be available.

When will Bicillin L-A 600,000 units return?

The 600,000-unit prefilled syringe remains unavailable, with an expected return-to-supply date of 30 November 2027.

What can replace Bicillin L-A during the shortage?

The TGA has approved overseas-registered benzathine benzylpenicillin products including Lentocilin S 1200 from Portugal and Benzetacil from Spain. A UK-registered alternative has also been approved but is currently unavailable. A clinician must determine which product, if any, is appropriate for a particular patient.

Are Bicillin L-A alternatives covered by the PBS?

Yes. The TGA states that all three approved overseas-registered benzathine benzylpenicillin alternatives are subsidised through the Pharmaceutical Benefits Scheme, although actual availability varies.

Why is Bicillin L-A important for rheumatic fever?

Regular benzathine benzylpenicillin injections are used to help prevent recurrent acute rheumatic fever, which can contribute to long-term heart damage and rheumatic heart disease.

Can I skip an injection if Bicillin L-A is unavailable?

Patients should not independently skip or postpone prescribed injections. The appropriate action depends on the condition being treated and the individual’s clinical circumstances. Contact the treating healthcare professional promptly if a scheduled injection may be affected.


Reviewed by: Dr Mattias Hagman, PhD

Editorial review: This article was prepared using the Australian Therapeutic Goods Administration’s 6 November 2026 Bicillin L-A shortage update, the TGA medicine shortages database and official information concerning Section 19A overseas-registered alternatives. It distinguishes the two Bicillin L-A strengths, the estimated return-to-supply dates, PBS subsidy, product availability and safety considerations associated with imported formulations.

Last reviewed: 7 November 2026

Sources and verification

MediSearcher reviewed the following primary regulatory sources:

MediSearcher provides general information about medicines, medicine shortages and healthcare regulation. This article does not provide personal medical advice. Benzathine benzylpenicillin treatment must be prescribed and administered under appropriate healthcare supervision. Patients should not change or interrupt prescribed treatment without consulting their treating healthcare professional. Product availability, expected resupply dates and reimbursement arrangements may change.